文献速递肝病

原发性硬化性胆管炎患者的胆汁酸谱及其预测肝功能失代偿的能力

Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation.
PubMed 文献 · Hepatology · 2021-06-15

在梅奥诊所400例原发性硬化性胆管炎(PSC)患者和302例健康对照的推导队列及挪威PSC研究中心的108例PSC验证队列中,采用质谱法检测血浆胆汁酸谱,发现PSC患者胆汁酸水平、结合型比例及初级与次级胆汁酸比值升高,UDCA增加总胆汁酸水平但降低胆酸和鹅去氧胆酸浓度,基于机器学习的PSC-BA谱评分预测5年肝功能失代偿的C统计量为0.95,验证队列为0.86。

要点

  • PSC患者较健康对照血浆胆汁酸水平、结合型比例及初级与次级胆汁酸比值升高。
  • UDCA增加PSC患者总血浆胆汁酸水平,同时降低胆酸和鹅去氧胆酸浓度。
  • PSC-BA谱评分预测5年肝功能失代偿的C统计量推导队列0.95、验证队列0.86。

核心结论

  • PSC患者血浆胆汁酸改变与已知的胆汁淤积机制、UDCA治疗及IBD一致。
  • 胆汁酸谱可预测未来肝功能失代偿,显示其临床潜力,可能适合用于临床试验。

研究设计与样本

  • 在梅奥诊所临床生化遗传实验室采用基于质谱的 assay 进行血浆胆汁酸谱检测。
  • 采用Cox比例风险(单变量)和梯度提升机(多变量)模型评估胆汁酸变量是否预测5年肝功能失代偿(定义为腹水、静脉曲张出血或脑病)。
  • 推导队列包括400例PSC患者和302例对照(梅奥诊所),验证队列包括108例PSC患者(挪威PSC研究中心)。

主要发现

  • PSC患者较对照胆汁酸水平、结合型比例及初级与次级胆汁酸比值升高。
  • UDCA增加总血浆胆汁酸水平,同时降低胆酸和鹅去氧胆酸浓度。
  • 无IBD的PSC患者初级与次级胆汁酸比值介于对照和溃疡性结肠炎患者之间。
  • 肝功能失代偿风险与多种胆汁酸浓度和结合型比例升高相关,而较高的G:T结合比值具有保护作用。
  • 机器学习模型PSC-BA谱评分(C统计量0.95)预测肝功能失代偿优于包括碱性磷酸酶在内的单项指标,验证队列表现良好(C统计量0.86)。

关键数值与推荐

  • 肝功能失代偿定义为腹水、静脉曲张出血或脑病。
  • PSC-BA谱评分预测5年肝功能失代偿的C统计量:推导队列0.95,验证队列0.86。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Altered bile acid (BA) homeostasis is an intrinsic facet of cholestatic liver diseases, but clinical usefulness of plasma BA assessment in primary sclerosing cholangitis (PSC) remains understudied. We performed BA profiling in a large retrospective cohort of patients with PSC and matched healthy controls, hypothesizing that plasma BA profiles vary among patients and have clinical utility. APPROACH AND RESULTS: Plasma BA profiling was performed in the Clinical Biochemical Genetics Laboratory at Mayo Clinic using a mass spectrometry based assay. Cox proportional hazard (univariate) and gradient boosting machines (multivariable) models were used to evaluate whether BA variables predict 5-year risk of hepatic decompensation (HD; defined as ascites, variceal hemorrhage, or encephalopathy). There were 400 patients with PSC and 302 controls in the derivation cohort (Mayo Clinic) and 108 patients with PSC in the validation cohort (Norwegian PSC Research Center). Patients with PSC had increased BA levels, conjugated fraction, and primary-to-secondary BA ratios relative to controls. Ursodeoxycholic acid (UDCA) increased total plasma BA level while lowering cholic acid and chenodeoxycholic acid concentrations. Patients without inflammatory bowel disease (IBD) had primary-to-secondary BA ratios between those of controls and patients with ulcerative colitis. HD risk was associated with increased concentration and conjugated fraction of many BA, whereas higher G:T conjugation ratios were protective. The machine-learning model, PSC-BA profile score (concordance statistic [C-statistic], 0.95), predicted HD better than individual measures, including alkaline phosphatase, and performed well in validation (C-statistic, 0.86). CONCLUSIONS: Patients with PSC demonstrated alterations of plasma BA consistent with known mechanisms of cholestasis, UDCA treatment, and IBD. Notably, BA profiles predicted future HD, establishing the clinical potential of BA profiling, which may be suited for use in clinical trials.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Mousa OY, Juran BD, McCauley BM, et al. Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. Hepatology. 2021. PMID: 33226645. doi:10.1002/hep.31652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。